Market Overview

Actavis' Growth 'Underappreciated,' Sterne Agee Says


In a report published Wednesday, Sterne Agee analyst Shibani Malhotra commented that Actavis plc's (NYSE: ACT) growth profile remains "underappreciated" and investors should buy shares following recent weakness related to a pending offering.

Malhotra wrote that the company's Investor Day presentation reaffirmed a positive view of management's ability to execute its long-term strategy and create "significant" shareholder value. The analyst added that its legacy pipeline remains offers several potential "attractive" opportunities within the next five years.

Malhotra explained that the company's earnings per share guidance increase to $16.30 - $17.30 from a prior $15.60 - $16.80 is "encouraging" and demonstrates the underlying organic growth trends of the combined Actavis/Allergan entity which "is not reflected in the current valuation."

Bottom line, the analyst concluded that "growth remains a top priority" and investors should take advantage of current weakness related to the near-term equity offering to build or add to positions.

Shares are Buy rated with a $315 price target.

Latest Ratings for ACT

Jun 2015Raymond JamesInitiates Coverage onOutperform
May 2015Deutsche BankMaintainsBuy
May 2015SusquehannaMaintainsPositive

View More Analyst Ratings for ACT
View the Latest Analyst Ratings

Posted-In: Allergan Shibani Malhotra Sterne AgeeAnalyst Color Analyst Ratings


Related Articles (ACT)

View Comments and Join the Discussion!

Latest Ratings

BYDNomura InstinetMaintains39.0
DEDeutsche BankMaintains175.0
EPRTCredit SuisseMaintains27.0
RYCredit SuisseMaintains112.0
EHTHCredit SuisseMaintains179.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at